TLPH

Talphera Inc

0.47

-0.03-5.05%

Pre Market: 0.5099 +0.0379 +8.03%08:43 04/24 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.4810/0.4971

TODAY RANGE0.4720-0.5044

VOL10

MARKET CAP9.68M

52 WEEK RANGE0.4500-1.270

AVG VOL (3M)55.24K

% TURNOVER0.41%

TURNOVER0

P/E (TTM)-0.9382

% RANGE6.52%

EPS(TTM)-0.5031

P/E(FORWARD)-0.9698

P/B1.005

BVPS0.4698

DIVIDEND--

P/S12.29

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP9.41M

SHARES OUTSTANDING20.50M

NEXT EARNINGS05/12-05/16

FREE FLOAT19.95M

LOT SIZE1

EX-DIV DATE10/26/2022

News

Press Releases

Financial Reports

Profile

NASDAQ·04/04 16:00
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?
TipRanks·04/04 02:04
Talphera CEO Makes Bold Move with Major Stock Purchase!
TipRanks·04/02 16:10
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks·04/02 00:02
Talphera, Inc. Earnings Call: Progress Amid Challenges
TipRanks·04/01 10:36
Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating
TipRanks·04/01 03:52
Talphera Reports 2024 Financial Results and Study Update
Seeking Alpha·03/31 22:34
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad
Benzinga·03/31 21:49
Talphera Expects Registrational NEPHRO CRRT Study To Be Completed By The End Of 2025
Benzinga·03/31 21:05
12 Health Care Stocks Moving In Monday's After-Market Session
Reuters·03/31 20:27
TALPHERA: EXPECTED TO PROVIDE CAPITAL THROUGH TARGET COMPLETION OF NEPHRO STUDY IN Q4 OF 2025
Dow Jones·03/31 20:23
*Talphera 4Q Rev $0.00 >TLPH
Dow Jones·03/31 20:23
*Talphera 4Q Loss/Shr 7c >TLPH
Dow Jones·03/31 20:23
*Talphera: Cash and Cash Equivalents Balance $8.9M as of Dec 31 >TLPH
TipRanks·03/31 20:11
Talphera reports Q4 EPS (7c) vs. (25c) last year
Benzinga·03/31 20:09
Talphera Q4 2024 GAAP EPS $(0.07) Beats $(0.16) Estimate

Same Industry

Name/Symbol

Change%

Price

McKesson

MCK

-0.42%

692.27

Biogen Inc

BIIB

-0.61%

118.17

Amgen Inc

AMGN

-0.18%

277.90

Shire

SHPG

0.00%

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

+17.53%

0.0295

Lilly Eli & Co

LLY

+0.23%

829.42

Celgene

CELG

0.00%

108.24

Therapeuticsmd Inc

TXMD

-2.70%

1.08

Johnson & Johnson

JNJ

-1.50%

155.38

Abbvie Inc

ABBV

+1.88%

177.05

Zoetis Inc

ZTS

+0.61%

150.91

Gilead Sciences Inc

GILD

+0.82%

106.38

Novo-Nordisk A/S

NVO

+2.32%

61.30

Bristol-Myers Squibb Co

BMY

-2.59%

48.53

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

-0.62%

22.39

Sanofi FR

SNY

+2.26%

53.02

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

-1.15%

110.13

Dr Reddys Labs

RDY

-1.44%

13.68

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.